ImpediMed (ASX:IPD) has shared that The National Comprehensive Cancer Network (NCCN) has updated its guidelines to recommend the regular use of bioimpedance spectroscopy (BIS) technology for lymphedema screening in all cancer survivors at risk.
The medical software technology company says this marks the first time BIS has been included in NCCN guidelines.
ImpediMed’s SOZO Digital Health Platform is the only FDA-cleared BIS technology for assessing lymphedema, with the updated guidelines expected to help establish BIS as a standard of care and accelerate adoption by private payers and medical providers.
Its share price is up 68% at 10:53am AEST.